Workflow
GZYK(002524)
icon
Search documents
光正眼科(002524) - 关于回购注销部分限制性股票减少注册资本暨通知债权人的公告
2025-09-04 10:30
光正眼科医院集团股份有限公司 关于回购注销部分限制性股票减少注册资本 光正眼科医院集团股份有限公司 证券代码:002524 证券简称:光正眼科 公告编号:2025-061 光正眼科医院集团股份有限公司 司自有资金。具体内容详见《光正眼科医院集团股份有限公司关于回购注销 2023 年限制性股票激励计划中部分激励对象已获授但尚未解除限售的限制性股票的 公告》(公告编号:2025-047)。 本次回购注销完成后,公司股份总数将由 518,467,074 股减少至 515,331,574 股,公司注册资本也将由 518,467,074 减少至 515,331,574 元。由于公司本次回购 注销部分限制性股票将涉及注册资本减少,根据《中华人民共和国公司法》(以 下简称"《公司法》")等相关法律、法规的规定,公司特此通知债权人,债权人 自接到公司通知之日起 30 日内、未接到通知的自本公告披露之日起 45 日内,有 权要求本公司清偿债务或者提供相应的担保。债权人未在规定期限内行使上述权 利的,本次回购注销将按法定程序继续实施。公司债权人如要求本公司清偿债务 或提供相应担保的,应根据《公司法》等法律、法规的有关规定向本公司 ...
光正眼科(002524) - 新疆天阳律师事务所关于光正眼科医院集团股份有限公司2025年度第二次临时股东大会法律意见书
2025-09-04 10:30
T&P 新疆天阳律师事务所 光正眼科 2025 年度第二次临时股东大会 2025 年度第二次临时股东大会 法律意见书 天阳证股字[2025]第 31 号 新疆天阳律师事务所 二○二五年九月 新疆天阳律师事务所 地址:新疆乌鲁木齐市水磨沟区红光山路 888 号绿城广场写字楼 2A 座 7 层 关于光正眼科医院集团股份有限公司 1 T&P 新疆天阳律师事务所 光正眼科 2025 年度第二次临时股东大会 新疆天阳律师事务所 关于光正眼科医院集团股份有限公司 法律意见书 天阳证股字[2025]第 31 号 致:光正眼科医院集团股份有限公司 新疆天阳律师事务所(下称"本所")接受光正眼科医院集团股份有限公司 (下称"公司")的委托,委派本所邵丽娅律师、李柯迪律师出席公司 2025 年 度第二次临时股东大会,根据《中华人民共和国公司法》(下称"《公司法》")、 《中华人民共和国证券法》(下称"《证券法》")、《上市公司股东会规则》 和《光正眼科医院集团股份有限公司章程》(下称"《公司章程》"),按照律 师行业公认的业务标准、道德规范和勤勉尽责精神,对有关的文件和事实进行核 查与验证,并出具法律意见。 本所律师已经对公司提 ...
光正眼科(002524) - 2025年第二次临时股东大会会议决议的公告
2025-09-04 10:30
光正眼科医院集团股份有限公司 证券代码:002524 证券简称:光正眼科 公告编号:2025-060 光正眼科医院集团股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 特别提示: 1、本次股东大会未出现否决议案的情况; 2、本次股东大会不涉及变更以往股东大会已通过的决议; 3、本次股东大会增加临时提案情况:2025 年 8 月 19 日,第六届董事会第 五次会议审议通过《关于工商变更企业类型并修订<公司章程>的议案》,同日公 司控股股东光正投资有限公司将审议通过后的上述议案以临时提案的方式提交 公司 2025 年第二次临时股东大会审议。对此,公司于 2025 年 8 月 22 日披露了 《关于持股 1%以上股东增加临时提案暨 2025 年度第二次临时股东大会补充通知 的公告》(公告编号:2025-058) 一、 会议召开情况 1.会议召开的日期、时间: 现场会议时间为:2025 年 9 月 4 日(星期四)下午 15:00; 网络投票时间为:2025 年 9 月 4 日。其中:通过深圳证券交易所交易系统 进行 ...
屈光手术业务增长放缓,眼科医疗企业欲借新技术谋突围
Di Yi Cai Jing· 2025-09-02 08:18
Core Viewpoint - The ophthalmology medical industry is experiencing a slowdown in the growth of refractive surgery revenue, with many companies reporting single-digit growth rates in this segment, while a few are still achieving double-digit growth. Group 1: Industry Overview - The refractive surgery business, a significant revenue source for private ophthalmology institutions, has shown a general trend of slowing growth in recent years [1] - Among five listed ophthalmology companies in A-shares, three reported refractive project revenue growth at single-digit levels or below in the first half of the year [1] - Specific growth figures include: - Puyi Eye Hospital (301239.SZ) with a 4.13% increase to 720 million yuan, accounting for 49% of total revenue [1] - He’s Eye Hospital (301103.SZ) with a 3.26% increase to 135 million yuan, accounting for 24% of total revenue [1] - Guangzheng Eye Hospital (002524.SZ) with a 0.32% increase to 142 million yuan, accounting for 32.71% of total revenue [1] - Aier Eye Hospital (300015.SZ) and Huaxia Eye Hospital (301267.SZ) are exceptions, achieving revenue growth rates of 11.4% and 13.75%, respectively [1] Group 2: Company Strategies - Aier Eye Hospital attributes its revenue growth in refractive projects to the acceptance of new surgical techniques such as All-Laser LASIK and the expansion of its medical network, enhancing patient coverage [3] - Puyi Eye Hospital is focusing on introducing authoritative expert teams and updating high-end diagnostic equipment to cultivate new growth points in the competitive refractive and vision care market [3] Group 3: Market Demand and Trends - The current refractive surgery patient population is divided into two categories: those with essential needs due to academic or professional requirements and those seeking aesthetic improvements [4] - Despite a stable demand from the essential needs group, the decision-making cycle for non-essential consumers is lengthening due to macroeconomic factors [4] - There is significant unmet demand in the refractive surgery market, with approximately 700 million myopic patients in China, but only about 1 million undergoing surgery annually [4] - The Z generation shows a personalized and urgent demand for vision correction, driving innovation and iteration in refractive surgery technologies [4] - Aierkon has introduced new refractive surgery solutions, such as All-Laser LASIK, which allows for personalized treatment based on various eye data [4] Group 4: Technology Adoption - Aierkon's All-Laser LASIK equipment has seen over 50,000 surgeries performed since its launch at the 2023 China International Import Expo, with over 100 hospitals equipped nationwide [5] - The company emphasizes the need for continued market education to enhance the penetration of new technologies [5]
屈光手术业务增长放缓 眼科医疗企业欲借新技术谋突围
Di Yi Cai Jing· 2025-09-02 08:18
Core Viewpoint - The refractive surgery business of private ophthalmology medical institutions is experiencing a slowdown in revenue growth, with several companies reporting single-digit growth rates in their refractive project revenues [1][2]. Group 1: Revenue Growth Analysis - Among five listed ophthalmology medical companies, three reported refractive project revenue growth at single-digit levels or below in the first half of the year. Specifically, Purui Eye Hospital (301239.SZ) saw a 4.13% increase to 720 million yuan, accounting for 49% of its total revenue; He’s Eye Hospital (301103.SZ) reported a 3.26% increase to 135 million yuan, making up 24% of its revenue; and Guangzheng Eye Hospital (002524.SZ) had a 0.32% increase to 142 million yuan, representing 32.71% of its revenue [1]. - In contrast, Aier Eye Hospital (300015.SZ) and Huaxia Eye Hospital (301267.SZ) managed to maintain double-digit growth rates in their refractive project revenues, with increases of 11.4% and 13.75%, respectively [1]. Group 2: Competitive Strategies - To navigate the competitive refractive surgery market, companies are leveraging new technologies. Aier Eye Hospital reported that its revenue growth in refractive projects is driven by the acceptance of new surgical techniques such as all-laser and full-femtosecond procedures, which have improved the business structure and increased average prices [2]. - Purui Eye Hospital is also responding to market competition by continuously introducing authoritative expert teams and updating high-end diagnostic equipment to cultivate new growth points [2]. Group 3: Market Demand and Trends - The current refractive surgery patient population can be divided into two groups: one with essential needs due to academic or professional requirements, and another seeking aesthetic improvements by eliminating glasses or contact lenses [2]. - Despite the large number of myopic patients in China, estimated at around 700 million, only about 1 million undergo refractive surgery annually, indicating significant unmet demand and potential for market penetration [3]. - The Z generation shows a personalized and urgent demand for vision correction, pushing for technological innovation and customization in refractive surgery [3].
76只股中线走稳 站上半年线
Group 1 - The Shanghai Composite Index closed at 3872.93 points, above the six-month moving average, with a gain of 0.39% [1] - The total trading volume of A-shares reached 228.56 billion yuan [1] - A total of 76 A-shares have surpassed the six-month moving average today, with notable stocks including Sanjiang Shopping, Jinyun Laser, and Kexin Machinery, showing divergence rates of 7.87%, 5.15%, and 5.13% respectively [1] Group 2 - The stocks with the highest divergence rates from the six-month moving average include: - Sanjiang Shopping: 10.03% increase, 4.63% turnover rate, latest price 11.96 yuan, divergence rate 7.87% [1] - Jinyun Laser: 6.03% increase, 6.89% turnover rate, latest price 17.76 yuan, divergence rate 5.15% [1] - Kexin Machinery: 5.96% increase, 12.01% turnover rate, latest price 13.51 yuan, divergence rate 5.13% [1] - Other notable stocks with smaller divergence rates include: - Sanbian Technology, Shanghai Ailu, and George White, which have just crossed the six-month moving average [1]
眼科医疗概念股异动拉升 莎普爱思午后涨停
Xin Lang Cai Jing· 2025-09-01 05:54
Group 1 - The ophthalmology medical concept stocks experienced a surge during trading, with Sharplife reaching a limit up [1] - Xingqi Eye Medicine rose over 10% in the afternoon session [1] - Lifang Pharmaceutical previously hit the limit up, indicating strong market interest [1] Group 2 - Other companies such as Baicheng Pharmaceutical, Aibo Medical, Guangzheng Eye Care, and He Shi Eye Care also saw increases in their stock prices [1]
负债率高企流动性吃紧 光正眼科陷财务难题
Bei Jing Shang Bao· 2025-08-26 01:05
Core Viewpoint - Guangzheng Eye Hospital is facing significant challenges including high debt levels and liquidity issues, despite its previous success in transitioning from a steel structure business to a medical eye care provider [1][4]. Financial Performance - In the first half of the year, the company reported a revenue of 436 million yuan, a year-on-year decrease of 9.49%, while the net profit attributable to shareholders was 1.42 million yuan, an increase of 11.38%. However, the net profit after deducting non-recurring items showed a loss of 3.28 million yuan [2][3]. - The second quarter saw a dramatic decline in net profit, with revenue of approximately 228 million yuan, down 19.26% year-on-year, and a net profit of about 845,200 yuan, down 95.77% [2]. Debt and Liquidity - The company's debt-to-asset ratio reached 90.25%, with total assets of 1.235 billion yuan and total liabilities of 1.114 billion yuan. This represents a significant increase from 80.99% in the same period last year [4][5]. - The liquidity ratios are concerning, with a current ratio of 0.367 and a quick ratio of 0.322, indicating potential short-term debt repayment challenges [4][5]. Cash and Receivables - As of the end of the reporting period, the company's cash balance decreased to 60.76 million yuan from 67.69 million yuan at the beginning of the period. Accounts receivable accounted for over 40% of current assets, totaling 162 million yuan [6]. - The company has significant overdue receivables, with amounts over three years reaching 46.58 million yuan and over five years at 35.31 million yuan [6]. Business Overview - Guangzheng Eye Hospital, established in 2001, has transitioned to focus primarily on the medical sector, with over 91.5% of its revenue coming from medical services, particularly cataract and refractive surgery projects [3][4]. - The company also has interests in steel structure and energy businesses, contributing 5.46% and 3.04% to revenue, respectively [3]. Goodwill and Impairment - The company has a significant goodwill balance of 243 million yuan, with a cumulative impairment provision of 374 million yuan due to previous acquisitions [7]. - In 2024, the company recorded a substantial goodwill impairment of 135 million yuan, leading to a net loss of 175 million yuan for the year [7]. Competitive Landscape - The eye care industry is becoming increasingly competitive, and Guangzheng Eye Hospital needs to enhance its brand influence and resource allocation to compete effectively against leading institutions [7].
光正眼科的财务难题:资产负债率居高不下,货币资金仅剩约6076万元
Bei Jing Shang Bao· 2025-08-25 12:22
Core Viewpoint - Guangzheng Eye Hospital, originally focused on steel structure business, has transformed into a medical ophthalmology company but is currently facing significant challenges including high debt levels and liquidity issues [1][5][11]. Financial Performance - In the first half of the year, the company reported operating revenue of approximately 436.15 million yuan, a decrease of 9.49% year-on-year [2][3]. - The net profit attributable to shareholders was 1.42 million yuan, an increase of 11.38% compared to the same period last year [2][3]. - The company experienced a significant decline in net profit in the second quarter, with a reported net profit of approximately 845,200 yuan, down 95.77% year-on-year [3][4]. Debt and Liquidity - As of the end of the first half, Guangzheng Eye Hospital's asset-liability ratio reached 90.25%, indicating a high level of debt [5][6]. - The current ratio was reported at 0.367 and the quick ratio at 0.322, both of which are below 1, suggesting potential short-term liquidity issues [6][7]. - The company's cash and cash equivalents decreased to 60.76 million yuan from 67.69 million yuan at the beginning of the period [9]. Revenue Composition - Over 90% of the company's revenue is derived from the medical sector, with approximately 399 million yuan from medical services, accounting for 91.5% of total revenue [4]. - Within the medical sector, cataract and refractive projects contributed 33.82% and 32.71% of revenue, respectively [4]. Asset Management - The company has a significant amount of accounts receivable, totaling 162 million yuan, which constitutes over 40% of current assets [10]. - The goodwill on the balance sheet amounts to 243 million yuan, with a cumulative impairment provision of 37.4 million yuan [10]. Competitive Landscape - The ophthalmology service sector is becoming increasingly competitive, and Guangzheng Eye Hospital needs to enhance its brand influence and resource reserves to differentiate itself from leading institutions [11].
光正眼科股价下跌2.09% 半年度净利润同比增长11.38%
Sou Hu Cai Jing· 2025-08-22 13:36
Group 1 - The stock price of Guangzheng Eye Hospital is reported at 4.68 yuan, down 0.10 yuan from the previous trading day, with a decline of 2.09% [1] - The highest intraday price reached 4.79 yuan, while the lowest dipped to 4.59 yuan, with a trading volume of 243,400 hands and a transaction amount of 113 million yuan [1] - The company operates in diversified business areas including ophthalmology hospital management and medical services, construction steel structure construction and sales, and natural gas sales, belonging to the medical services sector [1] Group 2 - In the first half of 2025, the company reported operating revenue of 436 million yuan, a year-on-year decrease of 9.49%, while the net profit attributable to shareholders increased by 11.38% to 1.4189 million yuan [1] - The net cash flow from operating activities was 29.8506 million yuan [1] - The shareholders' meeting has approved a buyback plan, with a maximum repurchase amount not exceeding 9.8432 million yuan [1] Group 3 - On August 22, the net inflow of main funds was 11.9908 million yuan, with a cumulative net inflow of 16.4365 million yuan over the past five days [1]